FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W70145905> ?p ?o ?g. }

• W70145905 endingPage "1530" @default.
• W70145905 startingPage "1519" @default.
• W70145905 abstract "Despite many therapeutic advances, mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic agents is unclear, especially among patients not receiving reperfusion therapy.To evaluate the effect of fondaparinux, a factor Xa inhibitor, when initiated early and given for up to 8 days vs usual care (placebo in those in whom unfractionated heparin [UFH] is not indicated [stratum 1] or unfractionated heparin for up to 48 hours followed by placebo for up to 8 days [stratum 2]) in patients with STEMI.Randomized double-blind comparison of fondaparinux 2.5 mg once daily or control for up to 8 days in 12,092 patients with STEMI from 447 hospitals in 41 countries (September 2003-January 2006). From day 3 through day 9, all patients received either fondaparinux or placebo according to the original randomized assignment.Composite of death or reinfarction at 30 days (primary) with secondary assessments at 9 days and at final follow-up (3 or 6 months).Death or reinfarction at 30 days was significantly reduced from 677 (11.2%) of 6056 patients in the control group to 585 (9.7%) of 6036 patients in the fondaparinux group (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.77-0.96; P = .008); absolute risk reduction, 1.5%; 95% CI, 0.4%-2.6%). These benefits were observed at 9 days (537 [8.9%] placebo vs 444 [7.4%] fondaparinux; HR, 0.83; 95% CI, 0.73-0.94; P = .003, and at study end (857 [14.8%] placebo vs 756 [13.4%] fondaparinux; HR, 0.88; 95% CI, 0.79-0.97; P = .008). Mortality was significantly reduced throughout the study. There was no heterogeneity of the effects of fondaparinux in the 2 strata by planned heparin use. However, there was no benefit in those undergoing primary percutaneous coronary intervention. In other patients in stratum 2, fondaparinux was superior to unfractionated heparin in preventing death or reinfarction at 30 days (HR, 0.82; 95% CI, 0.66-1.02; P = .08) and at study end (HR, 0.77; 95% CI, 0.64-0.93; P = .008). Significant benefits were observed in those receiving thrombolytic therapy (HR, 0.79; P = .003) and those not receiving any reperfusion therapy (HR, 0.80; P = .03). There was a tendency to fewer severe bleeds (79 for placebo vs 61 for fondaparinux; P = .13), with significantly fewer cardiac tamponade (48 vs 28; P = .02) with fondaparinux at 9 days.In patients with STEMI, particularly those not undergoing primary percutaneous coronary intervention, fondaparinux significantly reduces mortality and reinfarction without increasing bleeding and strokes.ClinicalTrials.gov Identifier NCT00064428." @default.
• W70145905 created "2016-06-24" @default.
• W70145905 creator A5001369923 @default.
• W70145905 creator A5007198463 @default.
• W70145905 creator A5007837184 @default.
• W70145905 creator A5012215765 @default.
• W70145905 creator A5018419311 @default.
• W70145905 creator A5024414499 @default.
• W70145905 creator A5039466154 @default.
• W70145905 creator A5047726859 @default.
• W70145905 creator A5049532621 @default.
• W70145905 creator A5053946443 @default.
• W70145905 creator A5063591215 @default.
• W70145905 creator A5065428733 @default.
• W70145905 date "2006-04-05" @default.
• W70145905 modified "2023-10-10" @default.
• W70145905 title "Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial" @default.
• W70145905 cites W1485646988 @default.
• W70145905 cites W1561801847 @default.
• W70145905 cites W1568597842 @default.
• W70145905 cites W165930709 @default.
• W70145905 cites W1763204026 @default.
• W70145905 cites W2015606026 @default.
• W70145905 cites W2025782661 @default.
• W70145905 cites W2047760971 @default.
• W70145905 cites W2059289792 @default.
• W70145905 cites W2107797912 @default.
• W70145905 cites W2111977341 @default.
• W70145905 cites W2133187714 @default.
• W70145905 cites W2146149132 @default.
• W70145905 cites W2152027086 @default.
• W70145905 cites W297892089 @default.
• W70145905 doi "https://doi.org/10.1001/jama.295.13.joc60038" @default.
• W70145905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16537725" @default.
• W70145905 hasPublicationYear "2006" @default.
• W70145905 type Work @default.
• W70145905 sameAs 70145905 @default.
• W70145905 citedByCount "800" @default.
• W70145905 countsByYear W701459052012 @default.
• W70145905 countsByYear W701459052013 @default.
• W70145905 countsByYear W701459052014 @default.
• W70145905 countsByYear W701459052015 @default.
• W70145905 countsByYear W701459052016 @default.
• W70145905 countsByYear W701459052017 @default.
• W70145905 countsByYear W701459052018 @default.
• W70145905 countsByYear W701459052019 @default.
• W70145905 countsByYear W701459052020 @default.
• W70145905 countsByYear W701459052021 @default.
• W70145905 countsByYear W701459052022 @default.
• W70145905 countsByYear W701459052023 @default.
• W70145905 crossrefType "journal-article" @default.
• W70145905 hasAuthorship W70145905A5001369923 @default.
• W70145905 hasAuthorship W70145905A5007198463 @default.
• W70145905 hasAuthorship W70145905A5007837184 @default.
• W70145905 hasAuthorship W70145905A5012215765 @default.
• W70145905 hasAuthorship W70145905A5018419311 @default.
• W70145905 hasAuthorship W70145905A5024414499 @default.
• W70145905 hasAuthorship W70145905A5039466154 @default.
• W70145905 hasAuthorship W70145905A5047726859 @default.
• W70145905 hasAuthorship W70145905A5049532621 @default.
• W70145905 hasAuthorship W70145905A5053946443 @default.
• W70145905 hasAuthorship W70145905A5063591215 @default.
• W70145905 hasAuthorship W70145905A5065428733 @default.
• W70145905 hasBestOaLocation W701459051 @default.
• W70145905 hasConcept C126322002 @default.
• W70145905 hasConcept C141071460 @default.
• W70145905 hasConcept C142454548 @default.
• W70145905 hasConcept C142724271 @default.
• W70145905 hasConcept C164705383 @default.
• W70145905 hasConcept C168563851 @default.
• W70145905 hasConcept C204787440 @default.
• W70145905 hasConcept C207103383 @default.
• W70145905 hasConcept C27081682 @default.
• W70145905 hasConcept C2776877702 @default.
• W70145905 hasConcept C2777557582 @default.
• W70145905 hasConcept C2780868729 @default.
• W70145905 hasConcept C2991741193 @default.
• W70145905 hasConcept C42219234 @default.
• W70145905 hasConcept C44249647 @default.
• W70145905 hasConcept C500558357 @default.
• W70145905 hasConcept C67774102 @default.
• W70145905 hasConcept C71924100 @default.
• W70145905 hasConcept C82789193 @default.
• W70145905 hasConceptScore W70145905C126322002 @default.
• W70145905 hasConceptScore W70145905C141071460 @default.
• W70145905 hasConceptScore W70145905C142454548 @default.
• W70145905 hasConceptScore W70145905C142724271 @default.
• W70145905 hasConceptScore W70145905C164705383 @default.
• W70145905 hasConceptScore W70145905C168563851 @default.
• W70145905 hasConceptScore W70145905C204787440 @default.
• W70145905 hasConceptScore W70145905C207103383 @default.
• W70145905 hasConceptScore W70145905C27081682 @default.
• W70145905 hasConceptScore W70145905C2776877702 @default.
• W70145905 hasConceptScore W70145905C2777557582 @default.
• W70145905 hasConceptScore W70145905C2780868729 @default.
• W70145905 hasConceptScore W70145905C2991741193 @default.
• W70145905 hasConceptScore W70145905C42219234 @default.
• W70145905 hasConceptScore W70145905C44249647 @default.

• next